Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Heritage Pharma

Pharmaceutical intelligence for Heritage Pharma with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
1
Assets
4

Recent signals(5)

RegulatoryAugust 5, 2026

FDA Approves Supplement for Risperidone by Heritage Pharma

The FDA has approved a supplement for the ANDA076228 application for Risperidone submitted by Heritage Pharma.

RegulatoryJuly 23, 2026

FDA Approval Update for Acetazolamide Supplement by Heritage Pharma

Heritage Pharma has received an approval update for a supplement application for Acetazolamide.

StrategyJuly 23, 2026

Heritage Pharma's Sertraline Hydrochloride ANDA077345 Receives AP Status

Heritage Pharma's application for Sertraline Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 13, 2026

Heritage Pharma's Sertraline Hydrochloride ANDA Submission Receives AP Status

Heritage Pharma's ANDA for Sertraline Hydrochloride has been granted Abbreviated Approval (AP) status.

StrategyJuly 13, 2026

FDA Approval Update for Risperidone by Heritage Pharma

Heritage Pharma has received an Abbreviated New Drug Application (ANDA) approval for Risperidone.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryAugust 5, 2026

FDA Approves Supplement for Risperidone by Heritage Pharma

The FDA has approved a supplement for the ANDA076228 application for Risperidone submitted by Heritage Pharma.

RegulatoryJuly 23, 2026

FDA Approval Update for Acetazolamide Supplement by Heritage Pharma

Heritage Pharma has received an approval update for a supplement application for Acetazolamide.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Acetazolamide →
Heritage →
Risperidone →
Sertraline Hydrochloride →

Therapeutic areas

Antidepressant →
Antipsychotic →
Carbonic Anhydrase Inhibitor →
Neurology →
Psychiatry →
Psychiatry · SSRI →
SSRI →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.